Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmbl647

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 27	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China

```
 NEWS 28  MAR 30  IMSPATENTS reloaded and enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009

=> file medline embase biosis caplus
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.22       0.22

FILE 'MEDLINE' ENTERED AT 12:07:20 ON 30 MAR 2009

FILE 'EMBASE' ENTERED AT 12:07:20 ON 30 MAR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:07:20 ON 30 MAR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s Porchet H?/AU
L1          261 PORCHET H?/AU

=> s l1 and prostate
L2            7 L1 AND PROSTATE

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3            4 DUP REM L2 (3 DUPLICATES REMOVED)

=> s Heimgarter F?/AU
L4            0 HEIMGARTER F?/AU

=> s Heimgartner F?/AU
L5           32 HEIMGARTNER F?/AU

=> s l5 and prostate
L6            2 L5 AND PROSTATE

=> dup rem l6
PROCESSING COMPLETED FOR L6
```

```
L7             2 DUP REM L6 (0 DUPLICATES REMOVED)

=> s Curdy C?/AU
L8            29 CURDY C?/AU

=> s l8 and prostate
L9             3 L8 AND PROSTATE

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10            3 DUP REM L9 (0 DUPLICATES REMOVED)

=> s Ducrey B?/AU
L11           16 DUCREY B?/AU

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12           10 DUP REM L11 (6 DUPLICATES REMOVED)

=> s l12 and prostate
L13            3 L12 AND PROSTATE

=> dis his

     (FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

     FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009
L1           261 S PORCHET H?/AU
L2             7 S L1 AND PROSTATE
L3             4 DUP REM L2 (3 DUPLICATES REMOVED)
L4             0 S HEIMGARTER F?/AU
L5            32 S HEIMGARTNER F?/AU
L6             2 S L5 AND PROSTATE
L7             2 DUP REM L6 (0 DUPLICATES REMOVED)
L8            29 S CURDY C?/AU
L9             3 S L8 AND PROSTATE
L10            3 DUP REM L9 (0 DUPLICATES REMOVED)
L11           16 S DUCREY B?/AU
L12           10 DUP REM L11 (6 DUPLICATES REMOVED)
L13            3 S L12 AND PROSTATE

=> dis ibib abs l3 1-4

L3   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:1487237  CAPLUS
DOCUMENT NUMBER:          150:24287
TITLE:                    Slow release pharmaceutical composition made of
                          microparticles comprising PLGA type copolymer and
                          peptide salt as active substance
INVENTOR(S):              Ducrey, Bertrand; Garrouste, Patrick; Curdy,
                          Catherine; Bardet, Marie-Anne; Porchet, Herve
                          ; Lundstrom, Eija; Heimgartner, Frederic
PATENT ASSIGNEE(S):       Debio Recherche Pharmaceutique S.A., Switz.
SOURCE:                   PCT Int. Appl., 19pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
```

WO 2008149320 A2 20081211 WO 2008-IB52241 20080606
WO 2008149320 A3 20090205
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606
WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles
made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 μm, D(v,0.5) is between 30 and 70 μm, D(v,0.9) is between 50 and 110 μm.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:612107 CAPLUS
DOCUMENT NUMBER: 143:120559
TITLE: Sustained release compositions of gonadotropin hormone releasing hormone and estrogen
INVENTOR(S): Porchet, Herve; Lundstrom, Eija; Curdy, Catherine; Bardet, Marie-Anne
PATENT ASSIGNEE(S): Debiopharm S.A., Switz.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063276	A1	20050714	WO 2004-IB4276	20041223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2003-IB6159 A 20031223
AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns.

of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flushes are minimized through the maintenance of a minimally adequate estrogen level. Combinations of polyestradiol phosphate and triptorelin were prepared for extemporaneous reconstitution.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965090 CAPLUS
DOCUMENT NUMBER: 141:389284
TITLE: Methods and compositions using gonadotropin hormone releasing hormone
INVENTOR(S): Porchet, Herve; Heimgartner, Frederic; Curdy, Catherine; Ducrey, Bertrand
PATENT ASSIGNEE(S): Debiopharm S.A., Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2523830	A1	20041111	CA 2004-2523830	20040430
EP 1617859	A1	20060125	EP 2004-730606	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009950	A	20060425	BR 2004-9950	20040430
CN 1780634	A	20060531	CN 2004-80011409	20040430
JP 2006525306	T	20061109	JP 2006-506555	20040430
MX 2005011299	A	20060124	MX 2005-11299	20051020
US 20070042040	A1	20070222	US 2006-554292	20060922
PRIORITY APPLN. INFO.:			WO 2003-IB1680 A	20030430
			WO 2004-IB1334 W	20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns. of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2003355146 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12887472
TITLE: Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
AUTHOR: Heyns C F; Simonin M-P; Grosgurin P; Schall R; Porchet H C
CORPORATE SOURCE: Department of Urology, University of Stellenbosch, Tygerberg Hospital, Western Cape, South Africa. (For the South African Triptorelin Study Group). cfh2@sun.ac.za
SOURCE: BJU international, (2003 Aug) Vol. 92, No. 3, pp. 226-31. Journal code: 100886721. ISSN: 1464-4096.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200309
ENTRY DATE: Entered STN: 31 Jul 2003
Last Updated on STN: 5 Sep 2003
Entered Medline: 4 Sep 2003

AB OBJECTIVE: To compare the efficacy of monthly administrations of the luteinizing hormone-releasing hormone agonists triptorelin pamoate and leuprolide acetate to induce and maintain castrate levels of serum testosterone in men with advanced prostate cancer. PATIENTS AND METHODS: Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg. The agent was injected intramuscularly every 28 days for nine injections. Primary endpoints were the percentages of men whose serum testosterone concentrations declined to and were maintained at or below castrate levels (</= 1.735 nmol/L or </= 500 ng/L) during 9 months (253 days) of treatment. Secondary endpoints were luteinizing hormone levels, bone pain, prostate specific antigen levels, quality of life, testosterone pharmacodynamics, survival, and safety variables. RESULTS: In all, 284 men received either triptorelin (140) or leuprolide (144). The percentage of men with castrate levels of serum testosterone was lower at 29 days for triptorelin than for leuprolide (91.2% vs 99.3%; point estimate - 8.0, 95% confidence interval - 16.9% to - 1.4%), but equivalent at 57 days (97.7% vs 97.1%). The mean (98.8% vs 97.3%) and cumulative (96.2% vs 91.2%) castration maintenance rates between 29 and 253 days were equivalent between the treatment groups. Secondary endpoints were equivalent between treatment groups except for the 9-month survival rate, which was significantly higher for triptorelin than for leuprolide (97.0% vs 90.5%; P = 0.033). Both treatments were well tolerated. CONCLUSION: Triptorelin reduced testosterone concentrations less rapidly, but maintained castration as effectively as leuprolide. There was no evidence that the slower onset of castration caused deleterious effects.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 27, 2009 (20090327/UP).

=> dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009
L1 261 S PORCHET H?/AU
L2 7 S L1 AND PROSTATE
L3 4 DUP REM L2 (3 DUPLICATES REMOVED)
L4 0 S HEIMGARTER F?/AU
L5 32 S HEIMGARTNER F?/AU
L6 2 S L5 AND PROSTATE
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)
L8 29 S CURDY C?/AU
L9 3 S L8 AND PROSTATE
L10 3 DUP REM L9 (0 DUPLICATES REMOVED)
L11 16 S DUCREY B?/AU
L12 10 DUP REM L11 (6 DUPLICATES REMOVED)
L13 3 S L12 AND PROSTATE

FILE 'STNGUIDE' ENTERED AT 12:11:28 ON 30 MAR 2009

=> dis ibib abs l6 1-2
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1487237 CAPLUS
DOCUMENT NUMBER: 150:24287
TITLE: Slow release pharmaceutical composition made of microparticles comprising PLGA type copolymer and peptide salt as active substance
INVENTOR(S): Ducrey, Bertrand; Garrouste, Patrick; Curdy, Catherine; Bardet, Marie-Anne; Porchet, Herve; Lundstrom, Eija; Heimgartner, Frederic
PATENT ASSIGNEE(S): Debio Recherche Pharmaceutique S.A., Switz.
SOURCE: PCT Int. Appl., 19pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008149320	A2	20081211	WO 2008-IB52241	20080606
WO 2008149320	A3	20090205		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606
WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 μm, D(v,0.5) is between 30 and 70 μm, D(v,0.9) is between 50 and 110 μm.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:965090 CAPLUS
DOCUMENT NUMBER: 141:389284
TITLE: Methods and compositions using gonadotropin hormone releasing hormone
INVENTOR(S): Porchet, Herve; Heimgartner, Frederic; Curdy, Catherine; Ducrey, Bertrand
PATENT ASSIGNEE(S): Debiopharm S.A., Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2523830	A1	20041111	CA 2004-2523830	20040430
EP 1617859	A1	20060125	EP 2004-730606	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009950	A	20060425	BR 2004-9950	20040430
CN 1780634	A	20060531	CN 2004-80011409	20040430
JP 2006525306	T	20061109	JP 2006-506555	20040430
MX 2005011299	A	20060124	MX 2005-11299	20051020
US 20070042040	A1	20070222	US 2006-554292	20060922

PRIORITY APPLN. INFO.: WO 2003-IB1680 A 20030430
WO 2004-IB1334 W 20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns. of the invention can be employed for an improved androgen deprivation

```
     therapy of prostate cancer, in which therapy loss of bone
     mineral d. and the occurrence and severity of hot flashes are minimized
     through the maintenance of a minimally adequate estrogen level.
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> dis his

     (FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

     FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009
L1           261 S PORCHET H?/AU
L2             7 S L1 AND PROSTATE
L3             4 DUP REM L2 (3 DUPLICATES REMOVED)
L4             0 S HEIMGARTER F?/AU
L5            32 S HEIMGARTNER F?/AU
L6             2 S L5 AND PROSTATE
L7             2 DUP REM L6 (0 DUPLICATES REMOVED)
L8            29 S CURDY C?/AU
L9             3 S L8 AND PROSTATE
L10            3 DUP REM L9 (0 DUPLICATES REMOVED)
L11           16 S DUCREY B?/AU
L12           10 DUP REM L11 (6 DUPLICATES REMOVED)
L13            3 S L12 AND PROSTATE

     FILE 'STNGUIDE' ENTERED AT 12:11:28 ON 30 MAR 2009

     FILE 'CAPLUS' ENTERED AT 12:12:35 ON 30 MAR 2009

     FILE 'STNGUIDE' ENTERED AT 12:12:35 ON 30 MAR 2009

=> dis ibib abs l10 1-3
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y



L10  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:1487237  CAPLUS
DOCUMENT NUMBER:          150:24287
TITLE:                    Slow release pharmaceutical composition made of
                          microparticles comprising PLGA type copolymer and
                          peptide salt as active substance
INVENTOR(S):              Ducrey, Bertrand; Garrouste, Patrick; Curdy,
                          Catherine; Bardet, Marie-Anne; Porchet, Herve;
                          Lundstrom, Eija; Heimgartner, Frederic
PATENT ASSIGNEE(S):       Debio Recherche Pharmaceutique S.A., Switz.
SOURCE:                   PCT Int. Appl., 19pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     WO 2008149320        A2    20081211    WO 2008-IB52241        20080606
     WO 2008149320        A3    20090205
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
```

KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606
WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles
made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 μm, D(v,0.5) is between 30 and 70 μm, D(v,0.9) is between 50 and 110 μm.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:612107 CAPLUS
DOCUMENT NUMBER: 143:120559
TITLE: Sustained release compositions of gonadotropin hormone releasing hormone and estrogen
INVENTOR(S): Porchet, Herve; Lundstrom, Eija; Curdy, Catherine; Bardet, Marie-Anne
PATENT ASSIGNEE(S): Debiopharm S.A., Switz.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063276	A1	20050714	WO 2004-IB4276	20041223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2003-IB6159 A 20031223

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns.
of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone
mineral d. and the occurrence and severity of hot flushes are minimized through the maintenance of a minimally adequate estrogen level.
Combinations of polyestradiol phosphate and triptorelin were prepared for

extemporaneous reconstitution.
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965090 CAPLUS
DOCUMENT NUMBER: 141:389284
TITLE: Methods and compositions using gonadotropin hormone releasing hormone
INVENTOR(S): Porchet, Herve; Heimgartner, Frederic; Curdy, Catherine; Ducrey, Bertrand
PATENT ASSIGNEE(S): Debiopharm S.A., Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2523830	A1	20041111	CA 2004-2523830	20040430
EP 1617859	A1	20060125	EP 2004-730606	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009950	A	20060425	BR 2004-9950	20040430
CN 1780634	A	20060531	CN 2004-80011409	20040430
JP 2006525306	T	20061109	JP 2006-506555	20040430
MX 2005011299	A	20060124	MX 2005-11299	20051020
US 20070042040	A1	20070222	US 2006-554292	20060922
PRIORITY APPLN. INFO.:			WO 2003-IB1680 A	20030430
			WO 2004-IB1334 W	20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns. of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009
L1 261 S PORCHET H?/AU

```
L2             7 S L1 AND PROSTATE
L3             4 DUP REM L2 (3 DUPLICATES REMOVED)
L4             0 S HEIMGARTER F?/AU
L5            32 S HEIMGARTNER F?/AU
L6             2 S L5 AND PROSTATE
L7             2 DUP REM L6 (0 DUPLICATES REMOVED)
L8            29 S CURDY C?/AU
L9             3 S L8 AND PROSTATE
L10            3 DUP REM L9 (0 DUPLICATES REMOVED)
L11           16 S DUCREY B?/AU
L12           10 DUP REM L11 (6 DUPLICATES REMOVED)
L13            3 S L12 AND PROSTATE

     FILE 'STNGUIDE' ENTERED AT 12:11:28 ON 30 MAR 2009

     FILE 'CAPLUS' ENTERED AT 12:12:35 ON 30 MAR 2009

     FILE 'STNGUIDE' ENTERED AT 12:12:35 ON 30 MAR 2009

     FILE 'CAPLUS' ENTERED AT 12:13:17 ON 30 MAR 2009

     FILE 'STNGUIDE' ENTERED AT 12:13:17 ON 30 MAR 2009

=> dis ibib abs l13 1-3
YOU HAVE REQUESTED DATA FROM FILE 'EMBASE, CAPLUS' - CONTINUE? (Y)/N:y



L13  ANSWER 1 OF 3  EMBASE  COPYRIGHT (c) 2009 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:   1994361901  EMBASE
TITLE:              [Current research on medicinal plants].
                    RECHERCHE ACTUELLE DANS LE DOMAINE DES PLANTES MEDICINALES.
AUTHOR:             Ducrey, B. (correspondence)
CORPORATE SOURCE:   Insti. de Pharmacognosie/Phytochimie, Universite de
                    Lausanne, BEP, 1015 Lausanne-Dorigny, Switzerland.
SOURCE:             Schweizer Apothekerzeitung, (1994) Vol. 132, No. 24, pp.
                    646-649.
                    ISSN: 0036-7508  CODEN: SAPOEF
COUNTRY:            Switzerland
DOCUMENT TYPE:      Journal; Conference Article; (Conference paper)
FILE SEGMENT:       016     Cancer
                    030     Clinical and Experimental Pharmacology
                    037     Drug Literature Index
                    004     Microbiology: Bacteriology, Mycology, Parasitology
                            and Virology
LANGUAGE:           French
SUMMARY LANGUAGE:   French
ENTRY DATE:         Entered STN: 29 Dec 1994
                    Last Updated on STN: 29 Dec 1994

L13  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:       2008:1487237  CAPLUS
DOCUMENT NUMBER:        150:24287
TITLE:                  Slow release pharmaceutical composition made of
                        microparticles comprising PLGA type copolymer and
                        peptide salt as active substance
INVENTOR(S):            Ducrey, Bertrand; Garrouste, Patrick; Curdy,
                        Catherine; Bardet, Marie-Anne; Porchet, Herve;
                        Lundstrom, Eija; Heimgartner, Frederic
PATENT ASSIGNEE(S):     Debio Recherche Pharmaceutique S.A., Switz.
```

SOURCE: PCT Int. Appl., 19pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008149320	A2	20081211	WO 2008-IB52241	20080606
WO 2008149320	A3	20090205		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606
WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 μm, D(v,0.5) is between 30 and 70 μm, D(v,0.9) is between 50 and 110 μm.

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965090 CAPLUS
DOCUMENT NUMBER: 141:389284
TITLE: Methods and compositions using gonadotropin hormone releasing hormone
INVENTOR(S): Porchet, Herve; Heimgartner, Frederic; Curdy, Catherine; Ducrey, Bertrand
PATENT ASSIGNEE(S): Debiopharm S.A., Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

CA 2523830 A1 20041111 CA 2004-2523830 20040430
EP 1617859 A1 20060125 EP 2004-730606 20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
BR 2004009950 A 20060425 BR 2004-9950 20040430
CN 1780634 A 20060531 CN 2004-80011409 20040430
JP 2006525306 T 20061109 JP 2006-506555 20040430
MX 2005011299 A 20060124 MX 2005-11299 20051020
US 20070042040 A1 20070222 US 2006-554292 20060922
PRIORITY APPLN. INFO.: WO 2003-IB1680 A 20030430
WO 2004-IB1334 W 20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns.
of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.07	65.91
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.20

STN INTERNATIONAL LOGOFF AT 12:14:25 ON 30 MAR 2009